Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a
Background and purpose Our aim was to identify early imaging surrogate markers of clinical progression in patients after the first demyelinating event suggestive of multiple sclerosis treated with weekly intramuscular interferon β‐1a. In a prospective observational study, the predictive role of base...
Gespeichert in:
| Veröffentlicht in: | European journal of neurology 2015-07, Vol.22 (7), p.1113-1123 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1123 |
|---|---|
| container_issue | 7 |
| container_start_page | 1113 |
| container_title | European journal of neurology |
| container_volume | 22 |
| creator | Uher, T. Horakova, D. Kalincik, T. Bergsland, N. Tyblova, M. Ramasamy, D. P. Seidl, Z. Vaneckova, M. Krasensky, J. Havrdova, E. Zivadinov, R. |
| description | Background and purpose
Our aim was to identify early imaging surrogate markers of clinical progression in patients after the first demyelinating event suggestive of multiple sclerosis treated with weekly intramuscular interferon β‐1a. In a prospective observational study, the predictive role of baseline and 6‐month changes in magnetic resonance imaging outcomes was investigated with respect to relapse activity and development of confirmed disability progression in patients after 48 months.
Methods
This study examined 210 patients. Multivariate Cox proportional hazard models were used to analyse predictors of relapse activity and confirmed disability progression after 48 months.
Results
Greater T2 lesion volume [hazard ratio (HR) 1.81; P = 0.005] and the presence of contrast‐enhancing lesions (HR 2.13; P |
| doi_str_mv | 10.1111/ene.12716 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1687997131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1687997131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3486-98f2ce03db7c4aafd9996f913a8dade650d374ec4b1925ee25e7cd45ece68d953</originalsourceid><addsrcrecordid>eNp1kcFuFCEYx0lT09bqoS_QcNTDtDDMDMPR1G2rqetFY-KFsPDNlpaBFZjUfRuvXn0EH8BnknbbvZWEAB-_75fAH6EjSk5oGafg4YTWnHY76IA2XV9Rxuhu2bOWVi0ldB-9TOmGEFLzmuyh_boVpCE1OUC_Zyq6NR7V0kO2GkdIwSuvAdtSs36JVxGM1TnEhMOAtbPeauVKOSwLnGzwWA0ZIm76v7_G4PN1wtZvwSK3KTiVweC09iaGEfBKZQs-J5wjPNzc2XxdunJU45T05FS8P0EcIBb_vz8VVa_Qi0G5BK8f10P09Xz25eyyuvp88eHs3VWlWdN3leiHWgNhZsF1o9RghBDdIChTvVEGupYYxhvQzYKKugUok2vTtKCh641o2SF6s_GWF_6YIGU52qTBOeUhTEnSrudCcMpoQd9uUB1DShEGuYrl2-JaUiLvk5ElGfmQTGGPH7XTYgSzJZ-iKMDpBrizDtbPm-RsPntSVpsOmzL83HaoeCs7zngrv80v5MfL8_mn7-S97Nl_BCatug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1687997131</pqid></control><display><type>article</type><title>Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Uher, T. ; Horakova, D. ; Kalincik, T. ; Bergsland, N. ; Tyblova, M. ; Ramasamy, D. P. ; Seidl, Z. ; Vaneckova, M. ; Krasensky, J. ; Havrdova, E. ; Zivadinov, R.</creator><creatorcontrib>Uher, T. ; Horakova, D. ; Kalincik, T. ; Bergsland, N. ; Tyblova, M. ; Ramasamy, D. P. ; Seidl, Z. ; Vaneckova, M. ; Krasensky, J. ; Havrdova, E. ; Zivadinov, R.</creatorcontrib><description>Background and purpose
Our aim was to identify early imaging surrogate markers of clinical progression in patients after the first demyelinating event suggestive of multiple sclerosis treated with weekly intramuscular interferon β‐1a. In a prospective observational study, the predictive role of baseline and 6‐month changes in magnetic resonance imaging outcomes was investigated with respect to relapse activity and development of confirmed disability progression in patients after 48 months.
Methods
This study examined 210 patients. Multivariate Cox proportional hazard models were used to analyse predictors of relapse activity and confirmed disability progression after 48 months.
Results
Greater T2 lesion volume [hazard ratio (HR) 1.81; P = 0.005] and the presence of contrast‐enhancing lesions (HR 2.13; P < 0.001) at baseline were significantly associated with increased cumulative risk of a second clinical attack over 48 months. A greater decrease of the corpus callosum volume (HR 2.74; P = 0.001) and greater lateral ventricle volume enlargement (HR 2.43; P = 0.002) at 6 months relative to baseline were associated with increased cumulative risk of a second clinical attack between months 6 and 48. In addition, increased risk of confirmed disability progression over 48 months in patients with greater lateral ventricle volume enlargement between baseline and 6 months (HR 4.70; P = 0.001) was detected.
Conclusions
A greater T2 lesion volume, the presence of contrast‐enhancing lesions at baseline, decrease of corpus callosum volume and lateral ventricle volume enlargement over the first 6 months in patients after the first demyelinating event treated with weekly intramuscular interferon β‐1a may assist in identification of patients with the highest risk of a second clinical attack and progression of disability.</description><identifier>ISSN: 1351-5101</identifier><identifier>EISSN: 1468-1331</identifier><identifier>DOI: 10.1111/ene.12716</identifier><identifier>PMID: 25904020</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adjuvants, Immunologic - administration & dosage ; Adult ; Biomarkers ; brain atrophy ; clinically isolated syndrome ; Demyelinating Diseases - diagnosis ; Demyelinating Diseases - drug therapy ; Demyelinating Diseases - pathology ; Demyelinating Diseases - physiopathology ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Injections, Intramuscular ; Interferon beta-1a - administration & dosage ; lesions ; Magnetic Resonance Imaging ; Male ; Middle Aged ; MRI ; multiple sclerosis ; predictors ; Recurrence</subject><ispartof>European journal of neurology, 2015-07, Vol.22 (7), p.1113-1123</ispartof><rights>2015 EAN</rights><rights>2015 EAN.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3486-98f2ce03db7c4aafd9996f913a8dade650d374ec4b1925ee25e7cd45ece68d953</citedby><cites>FETCH-LOGICAL-c3486-98f2ce03db7c4aafd9996f913a8dade650d374ec4b1925ee25e7cd45ece68d953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fene.12716$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fene.12716$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25904020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uher, T.</creatorcontrib><creatorcontrib>Horakova, D.</creatorcontrib><creatorcontrib>Kalincik, T.</creatorcontrib><creatorcontrib>Bergsland, N.</creatorcontrib><creatorcontrib>Tyblova, M.</creatorcontrib><creatorcontrib>Ramasamy, D. P.</creatorcontrib><creatorcontrib>Seidl, Z.</creatorcontrib><creatorcontrib>Vaneckova, M.</creatorcontrib><creatorcontrib>Krasensky, J.</creatorcontrib><creatorcontrib>Havrdova, E.</creatorcontrib><creatorcontrib>Zivadinov, R.</creatorcontrib><title>Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a</title><title>European journal of neurology</title><addtitle>Eur J Neurol</addtitle><description>Background and purpose
Our aim was to identify early imaging surrogate markers of clinical progression in patients after the first demyelinating event suggestive of multiple sclerosis treated with weekly intramuscular interferon β‐1a. In a prospective observational study, the predictive role of baseline and 6‐month changes in magnetic resonance imaging outcomes was investigated with respect to relapse activity and development of confirmed disability progression in patients after 48 months.
Methods
This study examined 210 patients. Multivariate Cox proportional hazard models were used to analyse predictors of relapse activity and confirmed disability progression after 48 months.
Results
Greater T2 lesion volume [hazard ratio (HR) 1.81; P = 0.005] and the presence of contrast‐enhancing lesions (HR 2.13; P < 0.001) at baseline were significantly associated with increased cumulative risk of a second clinical attack over 48 months. A greater decrease of the corpus callosum volume (HR 2.74; P = 0.001) and greater lateral ventricle volume enlargement (HR 2.43; P = 0.002) at 6 months relative to baseline were associated with increased cumulative risk of a second clinical attack between months 6 and 48. In addition, increased risk of confirmed disability progression over 48 months in patients with greater lateral ventricle volume enlargement between baseline and 6 months (HR 4.70; P = 0.001) was detected.
Conclusions
A greater T2 lesion volume, the presence of contrast‐enhancing lesions at baseline, decrease of corpus callosum volume and lateral ventricle volume enlargement over the first 6 months in patients after the first demyelinating event treated with weekly intramuscular interferon β‐1a may assist in identification of patients with the highest risk of a second clinical attack and progression of disability.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Adult</subject><subject>Biomarkers</subject><subject>brain atrophy</subject><subject>clinically isolated syndrome</subject><subject>Demyelinating Diseases - diagnosis</subject><subject>Demyelinating Diseases - drug therapy</subject><subject>Demyelinating Diseases - pathology</subject><subject>Demyelinating Diseases - physiopathology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Interferon beta-1a - administration & dosage</subject><subject>lesions</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Middle Aged</subject><subject>MRI</subject><subject>multiple sclerosis</subject><subject>predictors</subject><subject>Recurrence</subject><issn>1351-5101</issn><issn>1468-1331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFuFCEYx0lT09bqoS_QcNTDtDDMDMPR1G2rqetFY-KFsPDNlpaBFZjUfRuvXn0EH8BnknbbvZWEAB-_75fAH6EjSk5oGafg4YTWnHY76IA2XV9Rxuhu2bOWVi0ldB-9TOmGEFLzmuyh_boVpCE1OUC_Zyq6NR7V0kO2GkdIwSuvAdtSs36JVxGM1TnEhMOAtbPeauVKOSwLnGzwWA0ZIm76v7_G4PN1wtZvwSK3KTiVweC09iaGEfBKZQs-J5wjPNzc2XxdunJU45T05FS8P0EcIBb_vz8VVa_Qi0G5BK8f10P09Xz25eyyuvp88eHs3VWlWdN3leiHWgNhZsF1o9RghBDdIChTvVEGupYYxhvQzYKKugUok2vTtKCh641o2SF6s_GWF_6YIGU52qTBOeUhTEnSrudCcMpoQd9uUB1DShEGuYrl2-JaUiLvk5ElGfmQTGGPH7XTYgSzJZ-iKMDpBrizDtbPm-RsPntSVpsOmzL83HaoeCs7zngrv80v5MfL8_mn7-S97Nl_BCatug</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Uher, T.</creator><creator>Horakova, D.</creator><creator>Kalincik, T.</creator><creator>Bergsland, N.</creator><creator>Tyblova, M.</creator><creator>Ramasamy, D. P.</creator><creator>Seidl, Z.</creator><creator>Vaneckova, M.</creator><creator>Krasensky, J.</creator><creator>Havrdova, E.</creator><creator>Zivadinov, R.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201507</creationdate><title>Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a</title><author>Uher, T. ; Horakova, D. ; Kalincik, T. ; Bergsland, N. ; Tyblova, M. ; Ramasamy, D. P. ; Seidl, Z. ; Vaneckova, M. ; Krasensky, J. ; Havrdova, E. ; Zivadinov, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3486-98f2ce03db7c4aafd9996f913a8dade650d374ec4b1925ee25e7cd45ece68d953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Adult</topic><topic>Biomarkers</topic><topic>brain atrophy</topic><topic>clinically isolated syndrome</topic><topic>Demyelinating Diseases - diagnosis</topic><topic>Demyelinating Diseases - drug therapy</topic><topic>Demyelinating Diseases - pathology</topic><topic>Demyelinating Diseases - physiopathology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Interferon beta-1a - administration & dosage</topic><topic>lesions</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Middle Aged</topic><topic>MRI</topic><topic>multiple sclerosis</topic><topic>predictors</topic><topic>Recurrence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uher, T.</creatorcontrib><creatorcontrib>Horakova, D.</creatorcontrib><creatorcontrib>Kalincik, T.</creatorcontrib><creatorcontrib>Bergsland, N.</creatorcontrib><creatorcontrib>Tyblova, M.</creatorcontrib><creatorcontrib>Ramasamy, D. P.</creatorcontrib><creatorcontrib>Seidl, Z.</creatorcontrib><creatorcontrib>Vaneckova, M.</creatorcontrib><creatorcontrib>Krasensky, J.</creatorcontrib><creatorcontrib>Havrdova, E.</creatorcontrib><creatorcontrib>Zivadinov, R.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uher, T.</au><au>Horakova, D.</au><au>Kalincik, T.</au><au>Bergsland, N.</au><au>Tyblova, M.</au><au>Ramasamy, D. P.</au><au>Seidl, Z.</au><au>Vaneckova, M.</au><au>Krasensky, J.</au><au>Havrdova, E.</au><au>Zivadinov, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a</atitle><jtitle>European journal of neurology</jtitle><addtitle>Eur J Neurol</addtitle><date>2015-07</date><risdate>2015</risdate><volume>22</volume><issue>7</issue><spage>1113</spage><epage>1123</epage><pages>1113-1123</pages><issn>1351-5101</issn><eissn>1468-1331</eissn><abstract>Background and purpose
Our aim was to identify early imaging surrogate markers of clinical progression in patients after the first demyelinating event suggestive of multiple sclerosis treated with weekly intramuscular interferon β‐1a. In a prospective observational study, the predictive role of baseline and 6‐month changes in magnetic resonance imaging outcomes was investigated with respect to relapse activity and development of confirmed disability progression in patients after 48 months.
Methods
This study examined 210 patients. Multivariate Cox proportional hazard models were used to analyse predictors of relapse activity and confirmed disability progression after 48 months.
Results
Greater T2 lesion volume [hazard ratio (HR) 1.81; P = 0.005] and the presence of contrast‐enhancing lesions (HR 2.13; P < 0.001) at baseline were significantly associated with increased cumulative risk of a second clinical attack over 48 months. A greater decrease of the corpus callosum volume (HR 2.74; P = 0.001) and greater lateral ventricle volume enlargement (HR 2.43; P = 0.002) at 6 months relative to baseline were associated with increased cumulative risk of a second clinical attack between months 6 and 48. In addition, increased risk of confirmed disability progression over 48 months in patients with greater lateral ventricle volume enlargement between baseline and 6 months (HR 4.70; P = 0.001) was detected.
Conclusions
A greater T2 lesion volume, the presence of contrast‐enhancing lesions at baseline, decrease of corpus callosum volume and lateral ventricle volume enlargement over the first 6 months in patients after the first demyelinating event treated with weekly intramuscular interferon β‐1a may assist in identification of patients with the highest risk of a second clinical attack and progression of disability.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25904020</pmid><doi>10.1111/ene.12716</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-5101 |
| ispartof | European journal of neurology, 2015-07, Vol.22 (7), p.1113-1123 |
| issn | 1351-5101 1468-1331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1687997131 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adjuvants, Immunologic - administration & dosage Adult Biomarkers brain atrophy clinically isolated syndrome Demyelinating Diseases - diagnosis Demyelinating Diseases - drug therapy Demyelinating Diseases - pathology Demyelinating Diseases - physiopathology Disease Progression Female Follow-Up Studies Humans Injections, Intramuscular Interferon beta-1a - administration & dosage lesions Magnetic Resonance Imaging Male Middle Aged MRI multiple sclerosis predictors Recurrence |
| title | Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T12%3A55%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20magnetic%20resonance%20imaging%20predictors%20of%20clinical%20progression%20after%2048%C2%A0months%20in%20clinically%20isolated%20syndrome%20patients%20treated%20with%20intramuscular%20interferon%20%CE%B2-1a&rft.jtitle=European%20journal%20of%20neurology&rft.au=Uher,%20T.&rft.date=2015-07&rft.volume=22&rft.issue=7&rft.spage=1113&rft.epage=1123&rft.pages=1113-1123&rft.issn=1351-5101&rft.eissn=1468-1331&rft_id=info:doi/10.1111/ene.12716&rft_dat=%3Cproquest_cross%3E1687997131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1687997131&rft_id=info:pmid/25904020&rfr_iscdi=true |